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to 39.5% of eligible controls. Three patients died, (1 relapse, 2
infection) compared to 17 controls (9 relapse, 5 infection, 3
GvHD). Longer follow-up and immune recovery data are continu-
ing.
MSC use is feasible and safe without infusional toxicities and, as
our study seems to suggest, stabilize engraftment. Based on our
ﬁndings, where graft dysfunction, delayed hematological (immune)
recovery compromise the success of stem cell transplant outcome,
clinical randomized studies of MSCs are warranted.
Table 1 Patient characteristics and summary of results
PATIENTS
(n10)
CONTROLS
(n48)
Male:Female 6 (60%): 4 (40%) 29 (60%): 19 (40%)
Age (range) 8 years (2 – 15) 8 years (6 mo –18)
Malignant 7 (70%) 34 (70%)
Immune 2 (25%) 6 (13%)
Benign 1 (13%) 8 (17%)
Donor Male:Female 5:3 24:24
CD34 infused 31.8 (SD 3.1) 20 (SD 6.8). NS
CD3 infused 0.3 (SD 0.30) 0.68 (SD 0.7). NS
Overall survival
7/10 (70%)
FU 3-48 mo
31/48 (64%)
FU 2-6y
Days to Leukocyte
>1.0  109/l 12 (SD 1.9) 18 (SD 3.3) p0.0005
Days to Neutrophil
>0.5  109/l 13 (SD 1.5) 15 (SD 3.6) p0.14
Days to Platelets
>20  109/l 13 (SD 2.7) 21 (SD 14.7) p0.08
Days to Reticulocytes
>20 15 (SD 4.9) 35 (SD14.9) p0.04
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Seven patients, 3 leukemics, 2 patients with severe aplastic ane-
mia (SAA) and 2 SCID patients, underwent co-transplantation
with mesenchymal stem cells (MSC) and hematopoietic stem cells
(HSC). MSC were given in a pilot study to 4 patients and for graft
failure and retransplantation to 3 patients. HSCT donors were 3
HLA-identical siblings and 4 unrelated (2 matched and 1 major
mismatched unrelated and 1 mismatched unrelated cord blood).
Conditioning was myeloablative in 4 patients and RIC in 3 pa-
tients. MSC donors were HLA-identical siblings in 3 cases and
haploidentical in 4 cases. Passage 2-3 MSC were given at a dose of
1106/kg patient weight within 4 hours of the HSCT graft.
ANC 0.5109/L was reached in a median of 12 (range 10-28)
days. Platelets 30109/L was achieved in a median of 12 (8-36)
days. All patients had 100% donor chimerism for CD3, CD19 and
CD33 within 100 days. Acute GvHD grade 0-I was seen in 5
patients, two patients had grade II one proceeded to chronic
GvHD. One patient died of aspergillosis, the other patients are
alive and well.
One patient with SAA was on Cyclosporin for Henoch-Scho¨nlein
purpura since many years. This and graft failure resolved after
retransplantation of MSC  HSC.
Conclusion: MSC co-transplantation resulted in fast engraft-
ment of ANC and platelets and 100% donor chimerism, even in 3
patients regrafted for graft failure/rejection.
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Bone marrow or blood stem cell transplantation is the only cure
for 	-thalassemia major, however, despite myeloablative condi-
tioning regimens, the basic difﬁculty is a 15-30% graft failure rate
in these patients. Our hypothesis is that there may be a T-cell
dependent graft-versus-myelon effect that establishes and stabilizes
the engraftment of allogeneic blood stem cells in patients with
thalassemia major.
In a ﬁrst attempt, we assessed the CD3 chimerism early after
transplantation in a pediatric case series of six transplantations (2
related, 4 unrelated donors) transplanted from 2001 to 2004 with a
minimum follow-up period of 2 years after transplantation. The
donors were fully matched at HLA-DRB1 (high resolution) and
HLA-A and -B (low resolution). Peripheral blood CD3 chimerism
was determined at day30 (median). Chimerism of unfractionated
WBC was determined patients beginning day 13 (median) and
repeated until a stable engraftment or graft failure was achieved.
Patients (n  4) with a CD3 donor chimerism of 80% estab-
lished a long term engraftment and remained free of erythrocyte
transfusions (days 133, 775, 815, 2033). Two of these
patients developed a low total chimerism (minimum 42% on day
93, and 45% on day 42, resp.) after that a higher total donor
chimerism had been achieved (90% on day 17 and 92% on day
20, resp.). We stopped the immunosuppressive therapy in both
patients as soon as the result of the CD3 chimerism was available.
Both patients increased their total chimerism up to 98%; one
developed GvHD II° of the skin that resolved after steroid therapy
without impairment of the total chimerism.
Two patients with a CD3 donor chimerism10% lost their graft
completely, despite the fact, that one patient showed a high total
chimerism of 89% on day 6. One patient is again on the eryth-
rocyte transfusion programme, the other engrafted after re-trans-
plant from an unrelated donor.
We conclude that early determination of the CD3 chimerism
may be helpful for patient management. In addition, monitoring of
the CD3 chimerism should be included in transplant protocols for
beta-thalassemia major.
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Background
Allogeneic hematopoietic stem cell transplantation is a well es-
tablished treatment for hematological malignancies and other con-
ditions which can be associated with signiﬁcant morbidity and
mortality, particularly the development of severe acute graft-ver-
sus-host disease (GVHD). Severe steroid-refractory acute GVHD
continues to be associated with an 80-90% mortality despite the
use of many immunosuppressive agents with differing modes of
action. Mesenchymal stem cells (MSC) are rare, non-hemopoietic
cells found in the bone marrow, capable of differentiation into
bone, cartilage, muscle and fat cells. In addition to their potential
role in tissue repair, MSC have unique immunomodulatory prop-
erties. In vitro studies demonstrate they are both non-immuno-
genic and immunosuppressive. These property have been exploited
in the treatment of severe aGVHD. LeBlanc et al reported the ﬁrst
case of the successful treatment of steroid-refractory GVHD with
MSC in 2004 and in a recently reported EBMT study an overall
response rate of 69% was seen in 28 patients with steroid refractory
aGVHD. We report our experience with the use of MSC for
GVHD in 3 patients over the last 7 months.
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